Lifevantage

LFVNNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$66.032 M

$5.25 -12.14%

Close of 6 Nov 2026

As of 6 Nov 2026, Lifevantage (LFVN) has a market capitalization of $66.0M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$228.5M

#2232 by revenue

Earnings

$9.80M

#2033 by earnings

Shares outstanding

12,527,348

Latest filing cover page

P/E ratio

6.7

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#310Zhengye BiotechnologyZYBT$66.8M
#311Coya TherapeuticsCOYA$66.4M
#312LifevantageLFVN$66.0M
#313Stablecoin DevelopmentSDEV$65.7M
#314MAIA BiotechnologyMAIA$63.9M

What if Lifevantage were worth as much as…

Open the what-if tool →

Gold $28.2T

$2,242,901

Per share 427,626× higher

Bitcoin $1.53T

$121,359.46

Per share 23,138× higher

Apple $5.02T

$398,411.76

Per share 75,960× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Lifevantage are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.